secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001104659-21-134389
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q3 revenue $158.1M (+61% YoY), net loss $151.3M; raises FY2021 revenue guidance
--------------------------------------------------------------------------------

- Revenue $158.1M (+61.1% YoY); product revenue $150.7M (+61.5%); tests processed 407,300 (+55.4%).
- Net loss $151.3M (EPS -$1.63) vs loss $58.3M (-$0.72) in Q3 2020; operating loss $150.2M.
- Raises 2021 revenue guidance to $615-625M from prior; expects gross margin 49-52%; SG&A $500-520M; R&D $240-260M.
- Cash $1.0B; total debt $330.1M ($287.5M convertible notes principal; $50M credit line).
- Launched Prospera Kidney/Heart/Lung; exclusive license from Aarhus University for colorectal cancer screening biobank.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465921134389/0001104659-21-134389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465921134389/tm2131935d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-134389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer